Chemical Component Summary

NamePAMIDRONATE
Identifiers(3-amino-1-hydroxy-1-phosphono-propyl)phosphonic acid
FormulaC3 H11 N O7 P2
Molecular Weight235.07
TypeNON-POLYMER
Isomeric SMILESNCCC(O)(P(O)(O)=O)P(O)(O)=O
InChIInChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)
InChIKeyWRUUGTRCQOWXEG-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count24
Chiral Atom Count0
Chiral Atomsn/a
Bond Count23
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00282 Different stereochemistry
NamePamidronate
Groupsapproved
DescriptionPamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia]
Synonyms
  • Acide pamidronique
  • Acido pamidronico
  • Acidum pamidronicum
  • Pamidronic acid
  • Ribodroat
SaltsPamidronate Disodium
Brand Names
  • Aredia
  • Aredia 30mg
  • Aredia 90mg
  • Aredia Liq Inj 3mg/ml
  • PMS-pamidronate
Affected OrganismHumans and other mammals
IndicationFor the treatment of moderate or severe hypercalcemia associated with malignancy
PharmacologyPamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma.
Mechanism of actionThe mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Route of administrationIntravenous
Categories
  • Anti-Inflammatory Agents
  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Chemical Actions and Uses
  • Diphosphonates
ATC-CodeM05BA03
AHFS-Code92:00.00
CAS number40391-99-9

Drug Targets

NameSequence SearchPharmacological ActionActions
Farnesyl pyrophosphate synthaseMPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCW...yesinhibitor
yesantagonist
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682